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For the first time, the X-ray structure of nicotinamide riboside could be determined. Five nicotinamide 
riboside (NR) derivatives in their native, thioamide and triacetyl protected form could be crystallized as 
their chloride and bromide salts. The single crystals were obtained with the help of the vapour diffusion 
technique. The use of the much slower layering technique for crystallization led to the decomposition of 
the nicotinamide ribosides yielding the corresponding nicotinamide salts. The χ torsion angles of the five 
nicotinamide riboside derivatives were compared with those obtained from the two NAD crystal and the 




Nicotinamide riboside (NR) is a naturally occurring nucleoside present in almost all living organisms. 
Even though the metabolic pathway of NR has yet to be fully understood, recent studies imply that NR 
is a potent nicotinamide adenine dinucleotide (NAD+) precursor1-3 and an additional vitamin B3 form.4 
The discovery of nicotinamide riboside kinases (NRK 1 and 2) in humans implied that an NRK-
dependent pathway should exist in humans.5 This hypothesis was proven to be correct for mammalian 
cells in 2016.1 Yang et al. showed that NR treated cells have a 270% increase in NAD+ production 
compared to control experiments.6 This implied a greater potency of NR than nicotinamide or nicotinic 
acid as neither of them have been able to induce such high levels of NAD+. NR is a promising candidate 
for the treatment of several conditions including metabolic and neurodegenerative diseases and has 
received the GRAS (generally recognised as safe) status from FDA. Therefore it can be consumed as a 
food supplement.7 A recent study showed that permanent supply of nicotinamide riboside increases the 
NAD+ level in middle age to elderly persons.8 Finally, the concentration of NR in cow milk was found 
to be at lower M levels.9 In a recent patent, a crystalline form of nicotinamide ribose chloride was 
described to have advantageous properties relative to amorphous forms, e.g. since it may be better 
purified compared to amorphous forms.10 The crystalline chloride salt was obtained from an amorphous 
chloride salt by re-crystallization in a polar solvent such as methanol. We were surprised to see that not 
a single crystal structure of NR and of its derivatives that are not phosphate esters has been reported so 
far. Therefore, we started a study in order to determine the X-ray structures of the five NR derivatives 





Figure 1: The tested nicotinamide derivatives: nicotinamide--D-riboside chloride (1), nicotinamide--
D-riboside bromide (2), thionicotinamide--D-riboside bromide (3), nicotinamide--D-riboside 
triacetate bromide (4), and thionicotinamide--D-riboside triacetate bromide (5). 
 
2. Results & Discussion 
 
Initial crystallization attempts employed the layering technique, in which the compound of 
interest is dissolved in one dense solvent, placed in a narrow tube (normally an NMR tube). The 
solution is then carefully covered by a less dense anti-solvent. While this technique is known to 
produce nice crystals, it takes weeks until the mixing of the solvent and the anti-solvent results in 
the growth of single crystals.11 Initial crystallization attempts of nicotinamide ribose salts 
employing the layering technique with ethanol or methanol as solvents and isopropanol or 
tetrahydrofuran as anti-solvents yielded exclusively the corresponding protonated nicotinamide 
as a salt. These results can easily be explained by the well known instability of nicotinamide 
ribose salts. Oppenheimer determined the pH independent first order hydrolysis rate of 
nicotinamide ribose at 25°C as k = 10-5.8/s.12 Assuming that the layering experiment takes at least 
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2 weeks and inserting the above value of k into the equation E1, one can calculate that after this 
time already 85% of the nicotinamide ribose have been hydrolysed to give the nicotinamide. 
Therefore we decided to next employ the vapour diffusion technique, which can yield crystals as 
fast as within 15 hours.11 
 
E1 [ ] = [ ]  
 
2.1  Nicotinamide--D-riboside chloride (1) 
 
Single crystals were obtained by vapour diffusion at 23°C of 4 mg of 1 dissolved in ethanol against a 
reservoir of cyclohexane. The crystallographic data is summarised in Table 1. 1 crystallised in the 
orthorhombic, chiral space group P212121. The asymmetric unit consists of one molecule of 1 (Figure 2). 
The absolute configuration of the enantiomerically pure molecule was confirmed by the Flack parameter 
(-0.004(6)) and by comparison with the expected stereochemistry. The nitrogen of the amide group 
forms a hydrogen bond to the oxygen of a neighbouring amide group and another one to the chloride 
(N2-H2B O1(-0.5+x, -0.5-y, 1-z): 2.912(3) Å, N2-H2A Cl1(x, -1+y, z): 3.3359(19) Å). The alcohol 
groups of the riboside form hydrogen bonds to neighbouring alcohol groups and from the alcohol at C5 
to the chloride (O2-H2 O3(2-x, -0.5+y, 1.5-z): 2.7024(19) Å, O3-H3 O5(1-x, -0.5+y, 1.5-z): 2.6792(18) 
Å, O5-H5 Cl1: 3.0459(16) Å). Crystalline material, which was obtained by vapour diffusion of 1 
dissolved in methanol against a reservoir of tetrahydrofuran, crystallised in the same space group 









Figure 2: a) Displacement ellipsoid representation of 1, ellipsoids drawn at 50% probability.  
b) packing diagram of 1. 
 
Two patents for crystalline nicotinamide riboside chloride (1) were found, WO2016014927A210 from 
W.R. Grace & Co.-Conn. and WO2015186068A113 from GlaxoSmithKline, both filed in 2015. In both 
cases, the crystalline nicotinamide riboside chloride was characterised by powder X-ray diffraction 
(PXRD). In Figure 3 (top) the published PXRD pattern from patent WO2016014927A2 is shown. It 
looks very similar to the simulated PXRD pattern of 1 (Figure 3, bottom), thus indicating that it is 
indeed the same crystal structure. 
 




Figure 3: Top: Published PXRD pattern of solvate free 1 from patent WO2016014927A2.10 Bottom: 
PXRD pattern of 1 simulated from single crystal data. 
 
The published PXRD pattern of 1 from patent WO2015186068A1 is shown in Figure 4. It looks not as 
similar compared to the simulated PXRD pattern (Figure 3, bottom) as the pattern from patent 
WO2016014927A2. The peaks are slightly shifted to lower 2θ angles and differences occur in the 2θ 
range of 30° to 40°. As described in the patent the crystalline material was obtained from drying 
nicotinamide riboside chloride·0.9 methanol crystals under high vacuum and at ambient temperature for 
48 h. Therefore, traces of the solvate methanol (MeOH) could still be present which could be 
responsible for the differences in the PXRD pattern. Furthermore, this patent contains a PXRD pattern 




Figure 4: Published PXRD pattern of 1 with only trace amount of MeOH solvent from patent 
WO2015186068A1.13 
 
2.2 Nicotinamide--D-riboside bromide (2) 
 
Single crystals were obtained by vapour diffusion at 23°C of 4 mg of 2 dissolved in methanol against a 
reservoir of tetrahydrofuran. The crystallographic data is summarised in Table 1. 2 crystallised in the 
orthorhombic, chiral space group P212121. The asymmetric unit consists of one molecule of 2 (Figure 5). 
The structure is essentially isostructural with the chloride salt 1. The absolute configuration of the 
enantiomerically pure molecule was confirmed by the Flack parameter (0.012(4)) and by comparison 
with the expected stereochemistry. The nitrogen of the amide group forms a hydrogen bond to the 
oxygen of a neighbouring amide group and another one to the bromide (N2-H2B O1(0.5+x,-0.5-y,1-z): 
2.916(4) Å, N2-H2A Br1(x,-1+y,z): 3.476(3) Å). The alcohol groups of the riboside form hydrogen 
bonds to neighbouring alcohol groups and from the alcohol at C5 to the bromide (O2-H2 O3(-x, -0.5+y, 








Figure 5: a) Displacement ellipsoid representation of 2, ellipsoids drawn at 50% probability.  
b) packing diagram of 2. 
 
2.3 Thionicotinamide--D-riboside bromide (3) 
 
Single crystals were obtained by vapour diffusion at 23°C of 4 mg of 3 dissolved in methanol against a 
reservoir of tetrahydrofuran. The crystallographic data is summarised in Table 1. 3 crystallised in the 
orthorhombic, chiral space group P212121. The asymmetric unit consists of one molecule of 3 (Figure 6). 
The structure is essentially isostructural with the chloride and the bromide salts 1 and 2. The absolute 
configuration of the enantiomerically pure molecule was confirmed by the Flack parameter (-0.011(10)) 
and by comparison with the expected stereochemistry. The nitrogen of the thioamide group forms a 
hydrogen bond to the sulfur of a neighbouring thioamide group and another one to the bromide (N2-
H2B S1(-0.5+x,2.5-y,1-z): 3.428(3) Å, N2-H2A Br1(x,1+y,z): 3.461(3) Å). The alcohol groups of the 
riboside form hydrogen bonds to neighbouring alcohol groups and from the alcohol at C5 to the bromide 








Figure 6: a) Displacement ellipsoid representation of 3, ellipsoids drawn at 50% probability.  
b) packing diagram of 3. 
 
Table 1: Summary of crystal data and structure refinement of the isostructural salts 1, 2 and 3. 
 
 1 2 3 
Empirical formula [C11H15N2O5][Cl] [C11H15N2O5][Br] [C11H15N2O4S][Br] 
mol. weight [g/mol] 290.70 335.16 351.22 
Crystal system orthorhombic orthorhombic orthorhombic 
Space group  P212121 P212121 P212121 
a [Å] 4.93730(10) 4.99710(10) 5.04050(10) 
b [Å] 7.41700(10) 7.5323(2) 7.56260(10) 
c [Å] 34.8797(5) 35.0875(10) 36.3551(5) 
Volume [Å3] 1277.29(4) 1320.68(6) 1385.83(4) 
Z 4 4 4 
Density(calc.) [mg/m3] 1.512 1.686 1.683 
Abs. coeff. [mm-1] 2.851 3.131 5.580 
F(000) 608 680 712 
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Crystal size [mm3] 0.076 x 0.020 x 0.016 0.334 x 0.136 x 0.032 0.213 x 0.029 x 0.016 
Crystal description  colourless needle colourless plate light yellow needle 
Θ range [°] 5.072 to 78.782 2.322 to 32.934 4.866 to 78.463 
Index ranges -4≤h≤6, -8≤k≤9, -7≤h≤7, -11≤k≤10, -5≤h≤6, -9≤k≤6, 
 -44≤l≤43 -49≤l≤52 -46≤l≤41 
Reflections collected 11599 17105 12483 
Indep. reflections 2755 [Rint = 0.0283] 4398 [Rint = 0.0393] 2989 [Rint = 0.0261] 
Reflections obs. 2635 3986 2939 
Criterion for obs.  I > 2σ(I) I > 2σ(I) I > 2σ(I) 
Completeness to Θ [°] 99.9% to 67.684 99.9% to 25.242 99.9% to 67.684 
Absorption correction Gaussian semi-empirical from 
equivalents 
Gaussian 
Max. and min. 
transmission 
1.000 and 0.867 1.00000 and 0.74277 1.000 and 0.499 
Data / restraints / 
parameters 
2755 / 0 / 178 4398 / 0 / 184 2989 / 0 / 184 
Goodness-of-fit on F2 1.070 1.136 1.066 
Final R indices R1 = 0.0237, R1 = 0.0360, R1 = 0.0220, 
[I > 2σ(I)] wR2 = 0.0616 wR2 = 0.0642 wR2 = 0.0554 
R indices (all data) R1 = 0.0250, 
wR2 = 0.0622 
R1 = 0.0427, 
wR2 = 0.0653 
R1 = 0.0225, 
wR2 = 0.0556 
Flack parameter -0.005(6) 0.012(4) -0.011(10) 







2.4 Nicotinamide--D-riboside triacetate bromide (4) 
 
Single crystals were obtained by vapour diffusion at 23°C of 4 mg of 4 dissolved in ethanol against a 
reservoir of cyclohexane. The crystallographic data is summarised in Table 2. 4 crystallised in the 
monoclinic, chiral space group C2. The asymmetric unit consists of one molecule of 4 (Figure 7). The 
absolute configuration of the enantiomerically pure molecule was confirmed by the Flack parameter  
(-0.0038(18)) and by comparison with the expected stereochemistry. The nitrogen of the amide group 
forms two hydrogen bonds to two different bromide anions (N2-H2A Br1(0.5+x, 0.5+y, z): 3.4185(17) 
Å, N2-H2B Br1(1.5-x, 0.5+y, 2-z): 3.4051(15) Å). Crystalline material obtained by vapour diffusion of 
4 dissolved in methanol against a reservoir of tetrahydrofuran crystallised in the same space group C2 
and was therefore not fully characterised. It is of interest to note that Karrer and co-worker mentioned 
that 4 could not be obtained in a crystalline state.14 
 
a)    b)  
 
Figure 7: a) Displacement ellipsoid representation of 4, ellipsoids drawn at 50% probability. b) packing 
diagram of 4. 
 
In 2018, two groups from the Queen's University of Belfast and the ChromaDex company published a 
patent application, in which they showed the powder X-ray pattern of nicotinamide--D-riboside 
triacetate chloride (Figure 8).15 We took the coordinates of the corresponding bromide salt (4) and 
artificially substituted the bromide by a chloride ion. Without any further optimisation, we used these 
coordinates to simulate the X-ray the PXRD pattern of nicotinamide--D-riboside triacetate chloride 
(Figure 9). As one sees, the powder pattern is rather similar with the experimental one displayed in Figure 
8, indicating that the chloride salt described in patent application US20180134743A1 and the bromide of 




Figure 8: Published PXRD pattern of nicotinamide--D-riboside triacetate chloride from the patent 
application US20180134743A1.15  
 
 
Figure 9: Simulated PXRD pattern of nicotinamide--D-riboside triacetate chloride, taking the 
coordinates of the corresponding bromide salt (4) and substituting the bromide by a chloride ion. 
 
2.5 Thionicotinamide--D-riboside triacetate bromide (5) 
 
Single crystals were obtained by vapour diffusion at 23°C of 4 mg of 5 dissolved in methanol against a 
reservoir of tetrahydrofuran. The crystallographic data is summarised in Table 2. 5 crystallised in the 
triclinic, chiral space group P1. The asymmetric unit consists of two molecules of 5 (Figure 10). The 
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two molecules in the asymmetric unit possess almost the same configuration (see Figure S1 for an 
overlay of the two structures). The absolute configuration of the enantiomerically pure molecule was 
confirmed by the Flack parameter (-0.004(9)) and by comparison with the expected stereochemistry. 
The crystals are non-merohedral twins (ratio of 52:48) with the unit cells in the two different domains 
rotated by 180° perpendicular to the bc plane (Figure S2). The nitrogen of the amide group forms two 
hydrogen bonds to a bromide (N2-H2A Br21(1+x, 1+y, 1+z): 3.403(5) Å, N2-H2B Br1(x, 1+y, z): 






Figure 10: a) Displacement ellipsoid representation of 5, ellipsoids drawn at 50% probability. 





Table 2: Summary of crystal data and structure refinement of 4 and 5. 
 
 4 5 
Empirical formula [C17H21N2O8][Br] [C17H21N2O7S][Br] 
mol. weight [g/mol] 461.27 477.33 
Crystal system monoclinic triclinic 
Space group C2 P1 
a [Å]  15.9437(4) 7.02352(12) 
b [Å]  6.73890(10) 8.61252(13) 
c [Å]  19.1317(5) 18.1023(2) 
α [°] 90 90.2744(10) 
β [°] 109.064(3) 98.3915(11) 
γ [°] 90 110.7171(14) 
Volume [Å3] 1942.83(8) 1011.35(3) 
Z 4 2 
Density(calc.) [mg/m3] 1.577 1.567 
Abs. coeff. [mm−1] 2.163 4.111 
F(000) 944 488 
Crystal size [mm3] 0.227 x 0.187 x 0.055 0.12 x 0.09 x 0.012 
Crystal description  colourless plate yellow plate 
Θ range [°] 2.253 to 33.216 4.948 to 78.973 
Index ranges -22≤h≤24, -10≤k≤10, -28≤l≤27 -8≤h≤8, -10≤k≤10, -23≤l≤23 
Reflections collected 32123 14545 
Indep. reflections 6693 [Rint = 0.0244] 14545 
Reflections obs. 6367 14370 
Criterion for obs.  I > 2σ(I) I > 2σ(I) 
Completeness to Θ [°] 99.9% to 25.242 94.9% to 67.684 
Absorption correction semi-empirical from equivalents semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.512 1.00000 and 0.90407 
Data / restraints / 6693 / 1 / 256 14545 / 3 / 512 
parameters   
Goodness-of-fit on F2 1.036 1.040 
Final R indices [I > 2σ(I)] R1 = 0.0192, wR2 = 0.0494 R1 = 0.0369, wR2 = 0.0993 
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R indices (all data) R1 = 0.0211, wR2 = 0.0499 R1 = 0.0373, wR2 = 0.0996 
Flack parameter -0.0040(17) -0.004(9) 
Final ∆ρmax,min [e-/Å3] 0.41 and -0.24 0.93 and -0.31 
 
2.6 Isostructurality  
 
When comparing all structures 1-5, it becomes evident that the chloride and bromide salts of NR (1 and 
2) and the bromide salt of the corresponding thioamide (3) are all isostructural. However, the crystal 
structures of the triacetate bromide salt (4) and its thioamide derivative 5 are non-isostructural. The fact 
that chloride and bromide salts can form isostructural crystal structures is quite well known, see e.g. 
references 16,17 for two examples. It remains the question, why the substitution of the carbonyl oxygen 
with a sulfur atom to yield a thioamide gives raise to an isostructural structure in the case of salt 3 but not 
for 5? The nitrogen and the oxygen atom of the amide in the case of 2 are part of an extended hydrogen 
network as already discussed. Surprisingly, this hydrogen binding pattern remains the same, when the 
oxygen atom in 2 is substituted by a sulfur atom in 3, therefore generating the isostructural arrangement. 
On the other hand, neither the oxygen atom of the amide 4 nor the sulfur atom of the thioamide 5 are part 
of any hydrogen bonding. In both cases, both hydrogen atoms of the NH2 group are involved in a 
hydrogen bonding to one bromide anion each. These intermolecular interactions seem to allow different 
packing types in the cases of 4 and 5, making their structures non-isostructural. 
 
2.7 Torsion angle  of the nicotinamide riboside derivatives 
 
For all NR derivatives characterised above, the torsion angle χ was measured and their values are 
summarised in Table 3. For comparison, the only two other nicotinamide ribosides with comparable 
structures (Figure 11) were chosen from the Cambridge Structural Database, lithium (5’-nicotinamide-
ribosyl)-(5’-adenyl)-pyrophosphate dihydrate (Li(NAD)(H2O)2, 6)18 and (5’-nicotinamide-ribosyl)-(5’-
adenyl)-pyrophosphate tetrahydrate (H(NAD)(H2O)4, 7)19, in which the adenine is protonated. They 




Figure 11: Structures of 6 and 7. 
 
Table 3: Torsion angle χ of different NR derivatives. 
NR torsion angle [°] conformation space group Reference 
1 -136.09(15) anti P212121 This work 
2 -137.1(2) anti P212121 This work 
3 -137.8(2) anti P212121 This work 
4 26.2(2) syn C2 This work 
5 10.6(8) syn P1 This work 
6 -165.42 anti P212121 
18 
7 -150.32(9) anti P1 19 
protein structures containing 
nicotinamide riboside: 
    
PDB 2QT0 5.8 syn  20 
PDB 2QT1 -2.9 syn  20 
PDB 4QTN 6.4 syn  21 
 
The nicotinamide ribosides and their derivatives listed in Table 3 can be divided in two groups. The 
nicotinamide ribosides 1-3 with alcohol groups at the riboside and the two NAD structures 6 and 7 have 
a χ torsion angle of -135° to -165°. This corresponds to the nicotinamide being in the anti position. In 
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contrast, the torsion angles of the nicotinamide ribosides with triacetate groups 4 and 5 are between 10° 
and 30°, which corresponds to the nicotinamide unit being in the syn position. There are 3 protein 
structures containing also a nicotinamide riboside cation, in all these 3 cases the nicotinamide is in the 
syn conformation. The group of Eisenberg discussed the χ torsion angles of NAD in oxidoreductase 
enzymes co-structures and found that the torsion angles were in the syn and the anti conformation.22 The 





For the first time, the X-ray structures of nicotinamide riboside salts could be determined. All 
nicotinamide riboside derivatives (1-5) were successfully crystallised by the vapour diffusion method. In 
contrast, the crystallization setups with the layering technique led to the decomposition of the 
nicotinamide ribosides, because of the slow process of crystallization compared to the vapour diffusion. 
The obtained single crystals were measured on a Synergy diffractometer at 160 K and for each one of 
the compounds 1-5 the crystal structure could be determined. The 3 structures of nicotinamide--D-
riboside chloride (1), nicotinamide--D-riboside bromide (2) and thionicotinamide--D-riboside 
bromide (3) are isostructural. The χ torsion angles of the five nicotinamide riboside derivatives were 





Nicotinamide--D-riboside chloride (1), nicotinamide--D-riboside bromide (2)24, thionicotinamide--
D-riboside bromide (3), nicotinamide--D-riboside triacetate bromide (4)24,25, and thionicotinamide--
D-riboside triacetate bromide (5) were provided by Biosynth AG. Tetrahydropyran (≥99%) was 
purchased from Fluka. Methanol (≥99.9%), ethanol (≥99.9%), acetone (≥99.9%), acetonitrile (≥99.9%), 
chloroform (≥99%), cyclohexane (≥99.5%), tetrahydrofuran (THF, ≥99.9%) were purchased from Sigma 
Aldrich. All chemicals were used without further purification. 
 
4.1 Nicotinamide riboside derivatives 
 
All nicotinamide riboside derivatives were crystallised using the vapour diffusion technique.11 For 
each 4 mg of nicotinamide riboside was dissolved in about 1 ml of solvent in the inner tube as listed 
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in Table 4. Not dissolved particles were filtered off. The inner tube was then placed in the outer 
container. About 3 ml of antisolvent was added into the outer container and the container was then 
closed. The used solvents, antisolvents and the results are listed in Table 4. When crystals were 
observed the container was opened and the crystal removed for x-ray single crystal diffraction 
measurement. Exemplary crystals for each of the NR derivatives are shown in Figure 12. 
 
Table 4: Summary of vapour diffusion setups for the NR derivatives. 
 
NR Solvent Antisolvent result 
1 Methanol Tetrahydrofuran white clots, bad crystals 
1 Acetone Chloroform no crystals 
1 Acetonitrile Tetrahydropyran no crystals 
1 Ethanol Cyclohexane crystals 
2 Methanol Tetrahydrofuran crystals 
3 Methanol Tetrahydrofuran crystals 
4 Methanol Tetrahydrofuran crystals 
4 Ethanol Cyclohexane crystals 
5 Methanol Tetrahydrofuran bad needles 
5 Ethanol Cyclohexane twinned crystal 
 
   







Figure 12: Photos of the grown crystals of (a) 1, (b) 2, (c) 3, (d) 4, (e) 5. All scale bars are 200 µm. 
 
4.2 X-ray Single Crystal Diffusion 
 
Crystallographic data were collected at 160.0(1) K on a Rigaku-Oxford Diffraction XtaLAB Synergy-S 
dual source diffractometer. This is a kappa-axis four-circle goniometer with a Dectris Pilatus3 R 200K 
HPC (Hybrid Photon Counting) detector and Cu (for 1, 3, and 5) and Mo (for 2 and 4) PhotonJet 
microfocus X-ray sources. Suitable crystals were covered with oil (Infineum V8512, formerly known as 
Paratone N), placed on a nylon loop that is mounted in a CrystalCap Magnetic™ (Hampton Research) 
and immediately transferred to the diffractometer. The program suite CrysAlisPro was used for data 
collection, absorption correction and data reduction.26 The structures were solved with the dual-space 
algorithm using SHELXT27 and were refined by full-matrix least-squares methods on F2 with SHELXL-
201428 using the GUI Olex229. The graphical output and the simulation of the X-ray powder patterns was 
generated with the help of the program Mercury.30 CCDC 1903825-1903829 contain the supplementary 
crystallographic data for this paper. The data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. 
 
Supporting Information 
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
10.1021/acs.cgd.YYYYYY. Overlay of the two molecules in the asymmetric unit of 5 and orientation of 
the two non-merohedral twinning components in the crystal of 5. (PDF) 
 
Notes 
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various nicotinamide riboside derivatives. 
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The first single crystal growth of any nicotinamide ribose (NR) salt is reported. Vapour diffusion yielded the crystal 
structures of five different NR derivatives. The structures are compared with already reported powder patterns. 
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Figure S2: Orientation of the two non-merohedral twinning components in the crystal of 5. 
